Globeimmune Inc
OTC:GBIM
Globeimmune Inc
OTC:GBIM
Price:
0.0002 USD
Market Closed
Updated:
May 11, 2024
Globeimmune Inc
Research & Development
|
Globeimmune Inc
Research & Development Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Globeimmune Inc
OTC:GBIM
|
Research & Development
-$1.8m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$6.1B
|
CAGR 3-Years
18%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.7B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$4.6B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-17%
|
See Also
What is Globeimmune Inc's Research & Development?
Research & Development
-1.8m
USD
-1.8m
USD
Based on the financial report for Dec 31, 2015, Globeimmune Inc's Research & Development amounts to -1.8m USD.
What is Globeimmune Inc's Research & Development growth rate?
Research & Development CAGR 5Y
34%
34%
Over the last year, the Research & Development growth was 17%. The average annual Research & Development growth rates for Globeimmune Inc have been -3% over the past three years , 34% over the past five years .
You don't have any saved screeners yet
